secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0000950170-24-102554
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney refocuses Phase 3 program; discontinues PROACT 2, expects topline results Q3 2027
--------------------------------------------------------------------------------

- Discontinues ex-U.S. PROACT 2 trial; believes PROACT 1 alone may support FDA approval under RMAT designation.
- Estimated topline results from PROACT 1 by Q3 2027; expects $150-175M expense reduction.
- Cash runway extended to Q1 2027; focused on U.S. market for rilparencel in advanced CKD with type 2 diabetes.
- CEO cites positive REGEN-007 interim data as supporting urgency; RMAT designation granted Oct 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017024102554/0000950170-24-102554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017024102554/prok-20240822.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-102554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer